Avadel pharmaceuticals announces u.s. commercial launch of lumryz™ (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in adults living with narcolepsy

-lumryz is the first and only once-at-bedtime oxybate for people living with narcolepsy -once-nightly dosing regimen of lumryz has been found by fda to provide a major contribution to patient care over all twice-nightly oxybates dublin, ireland, june 05, 2023 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that lumryz is now commercially available. lumryz is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (eds) in adults with narcolepsy.
AVDL Ratings Summary
AVDL Quant Ranking